SciBase announces outcome of the preferential rights issue
Outcome of the Offering
SciBase Holding AB (publ) (”SciBase” or the ”Company”) today announces that the secured new share issue with preferential rights for existing shareholders (the ”Offering”) has been completed and will provide the Company with approximately SEK 75 million before deduction of transaction costs. A total of approximately SEK 39.2 million, corresponding to 46.1 percent of the full Offering was subscribed for. Approximately SEK 36.6 million, corresponding to 43.0 percent of the Offering, was subscribed for by way of subscription rights and approximately SEK 2.5 million, corresponding to 3.0 percent of the Offering, was subscribed for without exercise of subscription rights. The remaining part of the secured part of the Offering of SEK 75 million, corresponding to SEK 35.8 million or 42.0 percent of the total Offering amount of SEK 85 million, was allocated to guarantors.
Shares subscribed for without subscription rights have been allocated in accordance with the principles stated in the prospectus prepared in connection with the Offering and published on 20 November, 2017. Notice of the allocation of shares subscribed for without subscription rights will be sent out shortly to those who have been allocated shares.
In total, the Offering will provide SciBase with approximately SEK 65 million after deduction of transaction costs. The number of shares will increase from 8,284,768 to 16,618,101 shares when the new shares have been registered with the Swedish Companies Registration Office. When such registration has been made, paid subscribed shares (Sw. betalda tecknade aktier) will be converted into common shares. The preliminary record date for such conversion is 28 December 2017 whereby the paid subscribed shares will be converted into new shares on or about 2 January 2018. Trading in the new shares on Nasdaq First North is expected to start on the same day.
SciBase’s CEO Simon Grant comments:
“We are very pleased to finalise the rights issue and move forward with full focus on building the business. As outlined in our strategic plan, there are a number of exciting possibilities ahead for SciBase. Securing this financing will enable us to better address those opportunities, and the team heads into next year full of energy and focused on driving sales growth.”
Financial and legal advisers
Pareto Securities AB is financial adviser to SciBase and Setterwalls Advokatbyrå AB is legal adviser to SciBase and Pareto Securities AB in conjunction with the Offering. Avanza Bank is the Company’s certified adviser.
For further information, please contact:
Simon Grant, CEO
Phone: +46 72 887 43 99, e-mail: firstname.lastname@example.org
Michael Colérus, CFO
Phone: +46 70 341 34 72, e-mail: email@example.com
This information is information that SciBase Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 21:00 CET on 13 December, 2017.
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies.
SciBase is listed on Nasdaq First North (“SCIB”). Further information about the Company is available at www.scibase.com.
This press release is not an offer or solicitation to acquire shares in SciBase. A prospectus relating to the preferential rights issue referred to in this press release have been drawn up and filed with the Swedish Financial Supervisory Authority.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. SciBase does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.